An Inhalable Drug Delivery device is meant to administer medications that are to be inhaled deeply into the lungs. Drugs are delivered either by the nasal or oral respiratory route.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Inhalable Drug Delivery under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inhalable Drug Delivery and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Inhalable Drug Delivery under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ablynx NV
- Acorda Therapeutics Inc
- Actervis GmbH
- Activoris Medizintechnik GmbH
- Acu-Flow Ltd
- Aeon Research & Technology
- Aerophase Inc
- AFT Pharmaceuticals Ltd
- Alexza Pharmaceuticals Inc
- Baxter International Inc
- Bellerophon Therapeutics Inc
- Bridgesource Medical Corp
- Caddo Medical Technologies LLC
- California Northstate University College of Medicine
- Canigma A.L LTD
- Clyra Medical Technologies Inc
- Cognigenics Inc
- Creare LLC
- Cybin Inc
- Department of Biomedical Engineering Columbia University
- DesignWise Medical Inc (Inactive)
- Edixomed Ltd
- Gilbert Technologies BV
- HCmed Innovations Co Ltd
- HOLLO Medical Inc
- iDTx Systems, Inc.
- Inhalation Sciences Sweden AB
- Invero Pharma LLC
- IPI Legacy Liquidation Co
- Jupiter Research LLC
- KAER Biotherapeutics Corp
- Kanabo Research Ltd
- LTT Bio-Pharma Co Ltd
- Lupin Pharmaceuticals Inc
- Marquette University
- Medspray BV
- Meracle Pte Ltd
- Misti Pty Ltd
- Monash University
- Nemera La Verpilliere
- New Air, Inc.
- Next Safety, Inc.
- Nob Hill Therapeutics Inc
- Nobilis Therapeutics Inc
- OncoSec Medical Inc
- PARI GmbH
- Parion Sciences Inc
- Pharmosa Biopharm Inc
- Qnovia Inc
- Rhinomed Ltd
- Risproly
- RMIT University
- Rutgers Cancer Institute of New Jersey
- Sandoz International GmbH
- Scientific Horizons Consulting LLC
- Shenzhen Smoore Technology Ltd
- Sino Biopharmaceutical Ltd
- SolAeroMed Inc
- Stevanato Group SpA
- Stirling Pharma Inc
- Suzhou Wulian Medical Technology Co Ltd
- Suzhou Yihe Pharmaceutical Co Ltd
- Technology Commercialization Partners LLC
- Teleflex Inc
- Tetra Bio-Pharma Inc
- Teva Pharmaceutical Industries Ltd
- Texas Tech University Health Sciences Center
- Third Pole Inc
- Tianchen (Tianjin) Biotechnology Co Ltd
- Tiziana Life Sciences PLC
- University Hospital Southampton NHS Foundation Trust
- University of California San Diego
- University of Texas Health Science Center at Houston
- University of Texas Medical Branch at Galveston
- Vectura Group Plc
- Vero Biotech LLC
- Verona Pharma Plc
- Via Therapeutics LLC
- Vincent Medical Holdings Ltd
- Virpax Pharmaceuticals Inc
- VistaGen Therapeutics Inc
- VitalMIST
- Wellfully Ltd
- Wellinks Inc
- Windtree Therapeutics Inc

